Hikal Limited (BSE: 524735)
Health Care · Pharmaceuticals · IN
Rs216.30
-0.73% today · -15.6% 1Y
Hikal Limited (BSE: 524735) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $278.74M.
Over the last twelve months the share price has lost 15.6%, trading between 145.95 and 282.70.
Tweenvest scores Hikal Limited across four factors: quality 63/100, value 56/100, growth 9/100, dividend 4/100. Its strongest factor is quality.
524735 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $278.74M
- Revenue (TTM)
- $183.50M
- P/E
- —
- EPS
- -2.74
- Dividend yield
- 0.28%
- Beta (5Y)
- 0.60
- 52-week high
- Rs282.70
- 52-week low
- Rs145.95
- Avg volume (3M)
- —
- Shares outstanding
- 123.30M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,194.90 | -3.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.03 | -1.14% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.57 | -1.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.79% |
Figures last refreshed Aug 18, 2026.